pharmaboardroom.com Report : Visit Site

Technical data of the pharmaboardroom.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host pharmaboardroom.com. Currently, hosted in United States and its service provider is Merit Network Inc. .

the related websites

fmm.com.pa morgansrock.com piano-composer-teacher-london.co.uk dailymail.co.uk diocesissanjuandelamaguana.com optonet.inter.edu imaginesim.com strategicmaterials.com 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called nginx containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

download pdf register to download the report. already a member? login here username or e-mail password remember me reset password sign up or price: upgrade to first name:* first name required last name:* last name required organization name:* organization name is required organization type:* organization type is required select academic biotechnology/life sciences capital chemical construction/manufacturing/engineering finance/banking/accounting/venture government healthcare law firm media/publishing medical equipment/devices non profit pharmaceutical society.association/ngo other job role:* job role is required select analyst/researcher business development professional ceo/cto/president/vice president consultant director/ manager engineer licensing professional paralegal/legal executive press/pr/media professional portfolio manager professor purchaser regulatory affairs professional research scientist sales country/region: country/region is not valid select afghanistan Åland islands albania algeria american samoa andorra angola anguilla antarctica antigua and barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia, plurinational state of bonaire, sint eustatius and saba bosnia and herzegovina botswana bouvet island brazil british indian ocean territory brunei darussalam bulgaria burkina faso burundi cambodia cameroon canada cape verde cayman islands central african republic chad chile china christmas island cocos (keeling) islands colombia comoros congo congo, the democratic republic of the cook islands costa rica côte d'ivoire croatia cuba curaçao cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland islands (malvinas) faroe islands fiji finland france french guiana french polynesia french southern territories gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guernsey guinea guinea-bissau guyana haiti heard island and mcdonald islands holy see (vatican city state) honduras hong kong hungary iceland india indonesia iran, islamic republic of iraq ireland isle of man israel italy jamaica japan jersey jordan kazakhstan kenya kiribati korea, democratic people's republic of korea, republic of kuwait kyrgyzstan lao people's democratic republic latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia, the former yugoslav republic of madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mayotte mexico micronesia, federated states of moldova, republic of monaco mongolia montenegro montserrat morocco mozambique myanmar namibia nauru nepal netherlands new caledonia new zealand nicaragua niger nigeria niue norfolk island northern mariana islands norway oman pakistan palau palestinian territory panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar réunion romania russian federation rwanda saint barthélemy saint helena, ascension and tristan da cunha saint kitts and nevis saint lucia saint martin (french part) saint pierre and miquelon saint vincent and the grenadines samoa san marino sao tome and principe saudi arabia scotland senegal serbia seychelles sierra leone singapore sint maarten (dutch part) slovakia slovenia solomon islands somalia south africa south georgia and the south sandwich islands south sudan spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syrian arab republic taiwan, province of china tajikistan tanzania, united republic of thailand timor-leste togo tokelau tonga trinidad and tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states united states minor outlying islands uruguay uzbekistan vanuatu venezuela, bolivarian republic of viet nam virgin islands, british virgin islands, u.s. wallis and futuna western sahara yemen zambia zimbabwe email:* invalid email password:* invalid password password confirmation:* password confirmation doesn't match password strength password must be "weak" or stronger to complete registration, you must read and agree to our privacy and cookies policy. * get periodic e-mail updates and newsletters we respect your privacy please fix the errors above login x controls below part 1: personal information and privacy introduction 1.1 we are committed to safeguarding the privacy of our website visitors; this policy sets out how we will treat your personal information. 1.2 by using our website and agreeing to this policy, you consent to our use of cookies in accordance with the terms of this policy. collecting personal information 2.1 we may collect, store and use the following kinds of personal information: (a) information about your computer and about your visits to and use of this website (including your ip address, geographical location, browser type and version, operating system, referral source, length of visit, page views and website navigation paths); (b) information that you provide to us when registering with our website (including your email address) (c) information that you provide when completing your profile on our website (including your name, user name, country/region, employment details, password); (d) information that you provide to us for the purpose of subscribing to our email notifications and/or newsletters (including your name and email address); (e) information that you provide to us when using the services on our website, or that is generated in the course of the use of those services (including the timing, frequency and pattern of service use; (f) information relating to any purchases you make of our goods / services / goods and/or services or any other transactions that you enter into through our website (including your name, address, telephone number, email address and card details; (g) information that you post to our website for publication on the internet (including your user name, your profile pictures and the content of your posts); (h) information contained in or relating to any communications that you send to us or send through our website (including the communication content and meta data associated with the communication); (i) any other personal information that you choose to send to us; and 2.2 before you disclose to us the personal information of another person, you must obtain that person's consent to both the disclosure and the processing of that personal information in accordance with the terms of this policy. using your personal information 3.1 personal information submitted to us through our website will be used for the purposes specified in this policy or on the relevant pages of the website. 3.2 we may use your personal information to: (a) administer our website and business; (b) personalise our website for you; (c) enable your use of the services available on our website; (d) send you goods purchased through our website; (e) supply to you services purchased through our website; (f) send statements, invoices and payment reminders to you, and collect payments from you; (g) send you non-marketing commercial communications; (h) send you email notifications that you have specifically requested; (i) send you our email newsletter, if you have requested it (you can inform us at any time if you no longer require the newsletter); (j) send you marketing communications relating to our business or the businesses of carefully-selected third parties which we think may be of interest to you, by post or, where you have specifically agreed to this, by email or similar technology (you can inform us at any time if you no longer require marketing communications); (k) provide third parties with statistical information about our users (but those third parties will not be able to identify any individual user from that information); (l) deal with enquiries and complaints made by or about you relating to our website; (m) keep our website secure and prevent fraud; (n) verify compliance with the terms and conditions governing the use of our website (including monitoring private messages sent through our website private messaging service); 3.3 if you submit personal information for publication on our website, we will publish and otherwise use that information in accordance with the licence you grant to us. 3.4 your privacy settings can be used to limit the publication of your information on our website, and can be adjusted using privacy controls on the website. 3.5 we will not, without your express consent, supply your personal information to any third party for the purpose of their or any other third party's direct marketing. 3.6 all our website financial transactions are handled through our payment services provider, paypal. you can review the provider's privacy policy at https://www.paypal.com/gr/webapps/mpp/ua/privacy-full . we will share information with our payment services provider only to the extent necessary for the purposes of processing payments you make via our website, refunding such payments and dealing with complaints and queries relating to such payments and refunds. disclosing personal information 4.1 we may disclose your personal information to any of our employees, officers, insurers, professional advisers, agents, suppliers or subcontractors insofar as reasonably necessary for the purposes set out in this policy. 4.2 we may disclose your personal information to any member of our group of companies (this means our subsidiaries, our ultimate holding company and all its subsidiaries) insofar as reasonably necessary for the purposes set out in this policy. 4.3 we may disclose your personal information: (a) to the extent that we are required to do so by law; (b) in connection with any ongoing or prospective legal proceedings; (c) in order to establish, exercise or defend our legal rights (including providing information to others for the purposes of fraud prevention and reducing credit risk); (d) to the purchaser (or prospective purchaser) of any business or asset that we are (or are contemplating) selling; and (e) to any person who we reasonably believe may apply to a court or other competent authority for disclosure of that personal information where, in our reasonable opinion, such court or authority would be reasonably likely to order disclosure of that personal information. 4.4 except as provided in this policy, we will not provide your personal information to third parties. international data transfers 5.1 information that we collect may be stored and processed in and transferred between any of the countries in which we operate in order to enable us to use the information in accordance with this policy. 5.2 information that we collect may be transferred to the following countries which do not have data protection laws equivalent to those in force in the european economic area: the united states of america, russia, japan, china and india. 5.3 personal information that you publish on our website or submit for publication on our website may be available, via the internet, around the world. we cannot prevent the use or misuse of such information by others. 5.4 you expressly agree to the transfers of personal information described in this section 5. retaining personal information 6.1 this section 6 sets out our data retention policies and procedure, which are designed to help ensure that we comply with our legal obligations in relation to the retention and deletion of personal information. 6.2 personal information that we process for any purpose or purposes shall not be kept for longer than is necessary for that purpose or those purposes. 6.3 notwithstanding the other provisions of this section 6, we will retain documents (including electronic documents) containing personal data: (a) to the extent that we are required to do so by law; (b) if we believe that the documents may be relevant to any ongoing or prospective legal proceedings; and (c) in order to establish, exercise or defend our legal rights (including providing information to others for the purposes of fraud prevention and reducing credit risk). security of your personal information 7.1 we will take reasonable technical and organisational precautions to prevent the loss, misuse or alteration of your personal information. 7.2 we will store all the personal information you provide on our secure (password- and firewall-protected) servers. 7.3 all electronic financial transactions entered into through our website will be protected by encryption technology. 7.4 you acknowledge that the transmission of information over the internet is inherently insecure, and we cannot guarantee the security of data sent over the internet. 7.5 you are responsible for keeping the password you use for accessing our website confidential; we will not ask you for your password (except when you log in to our website). amendments 8.1 we may update this policy from time to time by publishing a new version on our website. 8.2 you should check this page occasionally to ensure you are happy with any changes to this policy. 8.3 we may notify you of changes to this policy [by email or through the private messaging system on our website. your rights 9.1 you may instruct us to provide you with any personal information we hold about you; provision of such information will be subject to: (a) the payment of a fee (currently fixed at gbp 10); and (b) the supply of appropriate evidence of your identity (for this purpose, we will usually accept a photocopy of your passport certified by a solicitor or bank plus an original copy of a utility bill showing your current address). 9.2 we may withhold personal information that you request to the extent permitted by law. 9.3 you may instruct us at any time not to process your personal information for marketing purposes. 9.4 in practice, you will usually either expressly agree in advance to our use of your personal information for marketing purposes, or we will provide you with an opportunity to opt out of the use of your personal information for marketing purposes. third party websites 10.1 our website includes hyperlinks to, and details of, third party websites. 10.2 we have no control over, and are not responsible for, the privacy policies and practices of third parties. updating information 11.1 please let us know if the personal information that we hold about you needs to be corrected or updated. part 2: cookies about cookies 1.1 a cookie is a file containing an identifier (a string of letters and numbers) that is sent by a web server to a web browser and is stored by the browser. the identifier is then sent back to the server each time the browser requests a page from the server. 1.2 cookies may be either "persistent" cookies or "session" cookies: a persistent cookie will be stored by a web browser and will remain valid until its set expiry date, unless deleted by the user before the expiry date; a session cookie, on the other hand, will expire at the end of the user session, when the web browser is closed. 1.3 cookies do not typically contain any information that personally identifies a user, but personal information that we store about you may be linked to the information stored in and obtained from cookies. 1.4 cookies can be used by web servers to identity and track users as they navigate different pages on a website and identify users returning to a website. our cookies 2.1 we use only both session and persistent cookies on our website. 2.2 the names of the cookies that we use on our website, and the purposes for which they are used, are set out below: (a) we use session cookie on our website to recognise a computer when a user visits the website and track users as they navigate the website; (b) we use secure cookie on our website to prevent fraud and improve the security of the website; (c) persistent cookies will be stored by a web browser and will remain valid until its set expiry date, unless deleted by the user before the expiry date; analytics cookies 3.1 we use google analytics to analyse the use of our website. 3.2 our analytics service provider generates statistical and other information about website use by means of cookies. 3.3 the analytics cookies used by our website have the following names: _utma, _utmt, _utmb, _utmc, _utmv and _utmz 3.4 the information generated relating to our website is used to create reports about the use of our website. 3.5 our analytics service provider's privacy policy is available at: http://www.google.com/policies/privacy/. third party cookies 4.1 our website also uses third party cookies. blocking cookies 5.1 most browsers allow you to refuse to accept cookies; for example: (a) in internet explorer (version 10) you can block cookies using the cookie handling override settings available by clicking "tools", "internet options", "privacy" and then "advanced"; (b) in firefox (version 24) you can block all cookies by clicking "tools", "options", "privacy", selecting "use custom settings for history" from the drop-down menu, and unticking "accept cookies from sites"; and (c) in chrome (version 29), you can block all cookies by accessing the "customise and control" menu, and clicking "settings", "show advanced settings" and "content settings", and then selecting "block sites from setting any data" under the "cookies" heading. 5.2 blocking all cookies will have a negative impact upon the usability of many websites. 5.3 if you block cookies, you will not be able to use all the features on our website. deleting cookies 6.1 you can delete cookies already stored on your computer; for example: (a) in internet explorer (version 10), you must manually delete cookie files (you can find instructions for doing so at http://support.microsoft.com/kb/278835); (b) in firefox (version 24), you can delete cookies by clicking "tools", "options" and "privacy", then selecting "use custom settings for history", clicking "show cookies", and then clicking "remove all cookies"; and (c) in chrome (version 29), you can delete all cookies by accessing the "customise and control" menu, and clicking "settings", "show advanced settings" and "clear browsing data", and then selecting "delete cookies and other site and plug-in data" before clicking "clear browsing data". 6.2 deleting cookies will have a negative impact on the usability of many websites. cookie preferences 7.1 you can manage your preferences relating to the use of cookies on our website by visiting: controls below part 3: our details data protection registration 1.1 we are registered as a data controller with the uk information commissioner's office. our details 2.1 this website is owned and operated by focus reports ltd . 2.2 we are registered in england and wales under registration number 7676770 , and our registered office is at lynton house, 7-12 tavistock square, london wc1h 9lt, united kingdom. 2.3 you can contact us by writing to the business address given above, by using our website contact form or by telephone on +441707828754 . cookie controls consent cookie name type set by contains expires allow decline _ga performance 1st party unique anonymous user id 2 years 72293 1527666247hclsreviewcanadamay2018.pdf login | register country reports -- menu stories strategy r&d biotech generics medtech manufacturing distribution regulation interviews big pharma mid-caps biotechs generics cmos & cros govt & regulators hospitals distribution medtech country reports facts & figures news press releases pr newswire directory events stories strategy r&d biotech generics medtech manufacturing distribution regulation interviews big pharma mid-caps biotechs generics cmos & cros govt & regulators hospitals distribution medtech country reports facts & figures news press releases pr newswire directory events stories interviews country reports × download latest country report download in this issue canada’s clinical trials and contract research excellence in this issue canada’s 250,000-patient medical cannabis industry comes of age in this issue interview: richard lajoie – president, valeant canada in this issue canada medtech facts & figures snapshot new issue canada download pharma reports click to download -- may 2018 -- pharma report -- -- may 2018 -- pharma report -- -- may 2018 -- pharma report -- -- april 2018 -- pharma report -- -- march 2018 -- pharma report -- -- march 2018 -- pharma report -- -- march 2018 -- pharma report -- -- february 2018 -- pharma report -- -- february 2018 -- pharma report -- -- january 2018 -- pharma report -- -- december 2017 -- pharma report -- -- december 2017 -- pharma report -- -- november 2017 -- pharma report -- -- november 2017 -- pharma report -- -- october 2017 -- pharma report -- -- september 2017 -- pharma report -- -- august 2017 -- pharma report -- -- july 2017 -- pharma report -- -- june 2017 -- pharma report -- -- june 2017 -- pharma report -- -- april 2017 -- pharma report -- -- april 2017 -- pharma report -- -- march 2017 -- pharma report -- -- february 2017 -- pharma report -- -- february 2017 -- pharma report -- -- january 2017 -- pharma report -- -- december 2016 -- pharma report -- -- december 2016 -- pharma report -- -- october 2016 -- pharma report -- -- september 2016 -- pharma report -- -- september 2016 -- pharma report -- -- august 2016 -- pharma report -- -- june 2016 -- pharma report -- -- may 2016 -- pharma report -- -- april 2016 -- pharma report -- -- april 2016 -- pharma report -- -- march 2016 -- pharma report -- -- february 2016 -- pharma report -- -- january 2016 -- pharma report -- -- december 2015 -- pharma report -- -- top story the four top tech disruptions in pharma in may 2018, pharmaboardroom’s readers were asked what they felt were the biggest new sources of disruption to the traditional pharma industry today. options included 3d bioprinting, blockchain storage, genomics and artificial intelligence. 3d ... canada the cannabis companies behaving like biotechs while many canadian medical cannabis outfits cover the entire value chain, from research and ... canada not so valeant after all valeant pharmaceuticals has taken the decision to rename itself in an effort to distance the ... china china’s greater bay area: spearheading innovation guangdong province and neighbouring hong kong have long been fundamental to china’s metamorphosis ... read more articles latest published interview : yuan qing – president, shenzhen life science and biotechnology association, china "shenzhen has a diverse range of companies working across antibiotics, oncology, chinese medicine, api and peptide manufacturing, and both small- and large-molecule drug development" yuan qing, president of the shenzhen life science and biotechnology association, shares his insights on the characteristics of the life sciences environment in shenzhen, the importance of the sectors as a key strategic priority for national and municipal governments, and … article the cannabis companies behaving like biotechs interviews : reinier schlatmann – ceo, philips central and eastern europe article the four top tech disruptions in pharma interviews : eva prada – director, british chamber of commerce in spain read more interviews pharma reports may 2018 canada may 2018 canada pharma report may 2018 ecuador may 2018 ecuador pharma report may 2018 poland may 2018 poland pharma report focus on the uk interview: lord o’shaughnessy – parliamentary under secretary of state for health, department of health and social care, uk "we possess three world-leading assets: our national health service, a thriving life sciences sector, and a formidable academic research base" 12.04.2018 interview: alexandre fasel – ambassador of switzerland to the uk 23.05.2018 uk life sciences firms struggle in post-brexit war for eu talent 09.01.2018 the uk life sciences ecosystem: a snapshot much of the new inward investment in the uk from international pharmaceutical… 27.02.2018 interview: haseeb ahmad country president, novartis uk only 14 months in position, uk country president at novartis, haseeb ahmad,… 04.06.2018 focus on the eu cardiology in poland: building a leading ecosystem "from the perspective of a cardiologist working everyday with patients, we have experienced positive change and drastic improvements over the last 20 years" piotr ponikowski 19.03.2018 interview: humberto arnés – director general, farmaindustria, spain 17.05.2018 top 20 pharma companies in poland ranking 09.05.2018 the baltics pharma report 2018 while lithuania, latvia and estonia have a lot in common – small,… 18.04.2018 interview: maria-ceu machado – president, infarmed, portugal maria-ceu machado, president of infarmed the national authority of medicines and health… 03.04.2018 focus on latin america interview: cesar m. rengifo – senior vice president & area director emerging markets west, gsk, brazil "gsk has been growing at a double-digit rate in latin america for the past two years and proudly stands as the fastest-growing multinational company in both brazil and latin america" 05.01.2018 the impact of government investment in health infrastructure in ecuador 13.04.2018 top 20 pharma companies in brazil ranking 2017 09.03.2018 mexico pharma report this report offers companies, investors, policymakers, and stakeholders crucial insight into the… 21.07.2017 interview: hector enriquez – general manager, laboratorios industriales farmaceuticos ecuadorianos (life) hector enriquez, general manager of laboratorios industriales farmaceuticos ecuadorianos (life), details the… 20.03.2018 focus on the greater bay area (guangdong, hong kong, macau) interview: tang dajie – founder and ceo, triwise capital, china "the chinese healthcare and life sciences industry is poised on the brink of explosive growth. shenzhen offers the best development opportunities for both companies and investors in this space" 14.05.2018 interview: grace zhou – dean, shenzhen international institute for biomedical research (siibr), china 16.05.2018 interview: albert cheung-hoi yu – chairman, hong kong biotechnology organization 13.06.2017 hong kong pharma report this report offers companies, investors, policymakers, and stakeholders crucial insight into the… 07.09.2017 the greater bay area (guangdong, hong kong, macau) macroeconomic snapshot the greater bay area (several cities in guangdong province in mainland china… 26.04.2018 key data pharma -- -- news from the boardroom 30.05.2018 pharmaboardroom releases ‘healthcare and life sciences review canada’ may 2018 pharma report pharmaboardroom today releases its new 58-page pharma report, healthcare & life sciences review canada may 2018. building on our january 2018 report on canada, this new edition of the healthcare & life sciences review delves deep into the myriad developments … pharmaboardroom releases ‘healthcare and life sciences review poland’ 2018 pharma report pharmaboardroom releases ‘healthcare and life sciences review baltics 2018’ tweets by @pharmaboardroom subscribe to receive our latest news and country reports each month ! top pharma interview -- facts & figures -- top 15 pharma companies in indonesia ranking the top 15 pharma companies in indonesia for 2016. local giant kalbe farma leads the way. ... facts & figures -- top 20 pharma companies in france ranking the following chart shows the top 20 pharma companies in france, ranked by sales for the year 2015. global giant ... facts & figures -- top 20 pharma companies in greece ranking in terms of value, global giants pfizer, novartis and sanofi lead the way in greece. click here to see more facts ... facts & figures -- top 10 pharma companies in the philippines ranking the top 10 pharmaceutical companies in the philippines by revenue. unilab leads the way, followed by pfizer and ... facts & figures -- top five pharma companies in czech republic ranking the following chart shows the top five pharma companies in the czech market, ranked by both value and volume. novartis ... 1 /5 most read interview: cristina campos – cpo head and country president, novartis portugal cristina campos is well known on the portuguese pharmaceutical circuit, directin... 486 views interview: haseeb ahmad country president, novartis uk only 14 months in position, uk country president at novartis, haseeb ahmad, shar... 131 views interview: jose escribano – founder, algenex, spain jose escribano, founder of spanish biotech success story algenex, discusses the ... 83 views about us pharmaboardroom.com about us -- pharmaboardroom provides free pharmaceutical industry trends, news and reports all over the world. this site is for senior professionals who want to understand local and global markets. contact us pharmaboardroom focus reports lynton house, 7-12 tavistock square london wc1h 9lt uk tel: +44 207 867 3717 email: [email protected] pharmaboardroom on linkedin -- follow us linkedin twitter home about us contact us privacy and cookies policy agile web development by byte9 -- x download pdf first name: last name: company: position: country: --- afghanistan albania algeria american samoa andorra angola anguilla antarctica antigua and barbuda argentina armenia arctic ocean aruba ashmore and cartier islands atlantic ocean australia austria azerbaijan bahamas bahrain baker island bangladesh barbados bassas da india belarus belgium belize benin bermuda bhutan bolivia bosnia and herzegovina botswana bouvet island brazil british virgin islands brunei bulgaria burkina faso burundi cambodia cameroon canada cape verde cayman islands central african republic chad chile china christmas island clipperton island cocos islands colombia comoros cook islands coral sea islands costa rica cote d'ivoire croatia cuba cyprus czech republic denmark democratic republic of the congo djibouti dominica dominican republic east timor ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia europa island falkland islands (islas malvinas) faroe islands fiji finland france french guiana french polynesia french southern and antarctic lands gabon gambia gaza strip georgia germany ghana gibraltar glorioso islands greece greenland grenada guadeloupe guam guatemala guernsey guinea guinea-bissau guyana haiti heard island and mcdonald islands honduras hong kong howland island hungary iceland india indian ocean indonesia iran iraq ireland isle of man israel italy jamaica jan mayen japan jarvis island jersey johnston atoll jordan juan de nova island kazakhstan kenya kingman reef kiribati kerguelen archipelago kosovo kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macau macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mayotte mexico micronesia midway islands moldova monaco mongolia montenegro montserrat morocco mozambique myanmar namibia nauru navassa island nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria niue norfolk island north korea north sea northern mariana islands norway oman pacific ocean pakistan palau palmyra atoll panama papua new guinea paracel islands paraguay peru philippines pitcairn islands poland portugal puerto rico qatar reunion republic of the congo romania russia rwanda saint helena saint kitts and nevis saint lucia saint pierre and miquelon saint vincent and the grenadines samoa san marino sao tome and principe saudi arabia senegal serbia seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa south georgia and the south sandwich islands south korea spain spratly islands sri lanka sudan suriname svalbard swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad and tobago tromelin island tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom usa uruguay uzbekistan vanuatu venezuela viet nam virgin islands wake island wallis and futuna west bank western sahara yemen yugoslavia zambia zimbabwe email: download pdf stories ▼ strategy r&d biotech generics medtech manufacturing distribution regulation interviews ▼ big pharma mid-caps biotechs generics cmos & cros govt & regulators hospitals distribution medtech country reports facts & figures news ▼ press releases pr newswire directory events stories strategy r&d biotech generics medtech manufacturing distribution regulation interviews big pharma mid-caps biotechs generics cmos & cros govt & regulators hospitals distribution medtech country reports facts & figures news press releases pr newswire directory events

URL analysis for pharmaboardroom.com

https://pharmaboardroom.com/interviews/interview-haseeb-ahmad-country-president-novartis-uk/
https://pharmaboardroom.com/country_reports/france-pharma-report/
https://pharmaboardroom.com/country_reports/ecuador-pharma-report-2018/
https://pharmaboardroom.com/interviews/interview-reinier-schlatmann-ceo-philips-central-and-eastern-europe/
https://pharmaboardroom.com/country_reports/egypt-pharma-report/
https://pharmaboardroom.com/facts/the-uk-life-sciences-ecosystem-a-snapshot/
https://pharmaboardroom.com/article/canadas-250000-patient-medical-cannabis-industry-comes-of-age/
https://pharmaboardroom.com/article/not-so-valeant-after-all/
https://pharmaboardroom.com/country_reports/ireland-pharma-report/
https://pharmaboardroom.com/article/uk-life-sciences-firms-struggle-in-post-brexit-war-for-eu-talent/
https://pharmaboardroom.com/pharma_report/hong-kong-pharma-report/
https://pharmaboardroom.com/country_reports/puerto-rico-pharma-report/
https://pharmaboardroom.com/mailto:[email protected]
https://pharmaboardroom.com/event-news/
https://pharmaboardroom.com/pharmaboardroom-releases-healthcare-and-life-sciences-review-canada-may-2018-pharma-report/

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: PHARMABOARDROOM.COM
Registry Domain ID: 1778848042_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.godaddy.com
Registrar URL: http://www.godaddy.com
Updated Date: 2017-03-20T12:12:10Z
Creation Date: 2013-02-07T01:09:01Z
Registry Expiry Date: 2018-02-07T01:09:01Z
Registrar: GoDaddy.com, LLC
Registrar IANA ID: 146
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: 480-624-2505
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Name Server: NS63.DOMAINCONTROL.COM
Name Server: NS64.DOMAINCONTROL.COM
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-08-16T22:23:23Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR GoDaddy.com, LLC

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =pharmaboardroom.com

  PORT 43

  TYPE domain

DOMAIN

  NAME pharmaboardroom.com

  CHANGED 2017-03-20

  CREATED 2013-02-07

STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientRenewProhibited https://icann.org/epp#clientRenewProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited

NSERVER

  NS63.DOMAINCONTROL.COM 216.69.185.42

  NS64.DOMAINCONTROL.COM 208.109.255.42

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .